Anavex Life Sciences Corp. (NASDAQ:AVXL) investors are cheering the news that the company has signed a material transfer agreement with Biogen (Cambridge, MA) under …
Yesterday morning, Anavex Life Sciences Corp (NASDAQ:AVXL) presented positive data after investigating its pipeline drug Anavex 2073, a sigma-1 receptor antagonist that could …
Anavex Life Sciences Corp. (NASDAQ:AVXL) shares rose nearly 14% after the clinical stage biopharma company presented preclinical data demonstrating that ANAVEX 2-73, a …
FBR analyst Christopher James offers insight on shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) after the company reported its third quarter financial results …
Anavex Life Sciences Corp. (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other …
Anavex Life Sciences Corp. (NASDAQ:AVXL) confirms the information in the July 27, 2016 press release announcing positive results from the Phase 2a Alzheimer’s …
In a research report released Tuesday, FBR analyst Christopher James reiterated an Outperform rating on shares of Anavex Life Sciences Corp. (NASDAQ:AVXL), with a $10 price …
Anavex Life Sciences Corp. (NASDAQ:AVXL) gave a first poster presentation on the 31-week safety data for mild-to-moderate Alzheimer’s Disease therapy drug 2-73, currently …
This weekend at the Alzheimer’s Association International Conference (AAIC), Anavex Life Sciences Corp. (NASDAQ:AVXL) presented the opening data for its Phase 2a Study …
Maxim’s healthcare analyst Jason Kolbert weighed in today on two names in his coverage universe, Anavex Life Sciences Corp. (NASDAQ:AVXL) and Pluristem Therapeutics Inc.
